NCT02720068: Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001)

NCT02720068
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis; Patients with prior anti-LAG3, anti-PD-1/L1, or anti-CTLA4 treatments
https://ClinicalTrials.gov/show/NCT02720068

Comments are closed.

Up ↑